F D C

F D C EBITDA per Employee

The EBITDA per Employee of F D C (FDC.NS) as of Oct 28, 2026 is 509,727.87 INR. In the previous year, EBITDA per Employee was 531,288.76 INR — a change of -4.06% (lower).

EBITDA per Employee

509,727.87INR

YoY

-4.06%

Last updated:

EBITDA per Employee of F D C is 2025 509,727.87 INR. EBITDA per Employee of F D C was 2024 531,288.76 INR. It decreases by -4.06% lower compared to the previous year.

The F D C EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
365,662.27 INR
Jan 1, 2019
360,737.76 INR
Jan 1, 2020
519,593.53 INR
Jan 1, 2021
520,896.89 INR
Jan 1, 2022
398,124.14 INR
Jan 1, 2023
393,870.68 INR
Jan 1, 2024
531,288.76 INR
Jan 1, 2025
509,727.87 INR
The F D C EBITDA per Employee history
YEAREBITDA per EmployeeYoY
509,727.87INR-4.06%
531,288.76INR+34.89%
393,870.68INR-1.07%
398,124.14INR-23.57%
520,896.89INR+0.25%
519,593.53INR+44.04%
360,737.76INR-1.35%
365,662.27INR-1.92%
372,814.19INR+3.87%
358,932.20INR+14.92%
312,318.74INR-4.10%
325,682.20INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

EBITDA per Employee of F D C is 509,727.87 INR in 2025.

EBITDA per Employee of F D C changed from 531,288.76 INR to 509,727.87 INR, representing a -4.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee F D C since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's F D C historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — F D C

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — F D C